Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 35, 2008, Pages 13003-13008

  Bai, Ailin ^a   Higham, Eileen ^b   Eisen, Herman N ^a   Wittrup, K Dane ^a,b   Chen, Jianzhu ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Immunotherapy; Influenza virus; T cell tolerance

Indexed keywords

EPITOPE; GAMMA INTERFERON; INFLUENZA VACCINE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CD8+ T LYMPHOCYTE; CLONE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; IMMUNOLOGICAL TOLERANCE; IN VIVO CULTURE; INFLUENZA VACCINATION; LUNG LYMPH FLOW; LYMPH NODE; LYMPHATIC DRAINAGE; LYMPHOCYTE SUBPOPULATION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE OF TRANSGENIC ADENOCARCINOMA MOUSE; T LYMPHOCYTE ACTIVATION; TARGET CELL; VIRUS ACTIVATION;

ADENOCARCINOMA; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS-PRIMING; CYTOKINES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; MALE; MICE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RATS; VACCINATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 51349149926     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0805599105     Document Type: Article

References (35)

1. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666-675.
2. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: A treatment for the masses. Science 305:200-205.
3. Stevanovic S (2002) Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2:514-520.
4. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
5. Lee PP, et al. (1999) Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 5:677-685.
6. Ochsenbein AF, et al. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96:2233-2238.
7. Spiotto MT, Fu YX, Schreiber H (2003) Tumor immunity meets autoimmunity: Antigen levels and dendritic cell maturation. Curr Opin Immunol 15:725-730.
8. Ochsenbein AF, et al. (2001) Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411:1058-1064.
9. Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47-64.
10. Lyman MA, Aung S, Biggs JA, Sherman LA (2004) A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 172:6558-6567.
11. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol 7:682-686.
12. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915.
13. Spiotto MT, et al. (2002) Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17:737-747.
14. Bai XF, et al. (2001) Local costimulation reinvigorates tumor-specific cytolytic T lymphocytes for experimental therapy in mice with large tumor burdens. J Immunol 167:3936-3943.
15. Ostrand-Rosenberg S (2004) Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 16:143-150.
16. Van Dyke T, Jacks T (2002) Cancer modeling in the modern era: Progress and challenges. Cell 108:135-144.
17. Greenberg NM, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92:3439-3443.
18. Willimsky G, Blankenstein T (2005) Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 437:141-146.
19. Blankenstein T (2007) Do autochthonous tumors interfere with effector T cell responses? Semin Cancer Biol 17:267-274.
20. Karnes RJ, Whelan CM, Kwon ED (2006) Immunotherapy for prostate cancer. Curr Pharm Des 12:807-817.
21. Whiteside TL, Parmiani G (1994) Tumor-infiltrating lymphocytes: Their phenotype, functions and clinical use. Cancer Immunol Immunother 39:15-21.
22. Chen J, Eisen HN, Kranz DM (2003) A model T-cell receptor system for studying memory T-cell development. Microbes Infect 5:233-240.
23. Zhang J, Thomas TZ, Kasper S, Matusik RJ (2000) A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141:4698-4710.
24. Shen CH, et al. (2008) Loss of IL-7R and IL-15R expression is associated with disappearance of memory T cells in respiratory tract following influenza infection. J Immunol 180:171-178.
25. Drake CG, et al. (2005) Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7:239-249.
26. Lees JR, et al. (2006) Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology 117:248-261.
27. Zheng X, Yin L, Liu Y, Zheng P (2004) Expression of tissue-specific autoantigens in the hematopoietic cells leads to activation-induced cell death of autoreactive T cells in the secondary lymphoid organs. Eur J Immunol 34:3126-3134.
28. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA (2007) Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178:1268-1276.
29. Leen AM, Rooney CM, Foster AE (2007) Improving T cell therapy for cancer. Annu Rev Immunol 25:243-265.
30. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R (2003) Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 77:4911-4927.
31. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
32. Clemente CG, et al. (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310.
33. Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217-223.
34. Chen ML, et al. (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA 102:419-424.
35. Kiniwa Y, et al. (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13:6947-6958.